scholarly journals Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines

2015 ◽  
Vol 372 (5) ◽  
pp. 447-455 ◽  
Author(s):  
Andrew E. Moran ◽  
Michelle C. Odden ◽  
Anusorn Thanataveerat ◽  
Keane Y. Tzong ◽  
Petra W. Rasmussen ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hypertension Therapy

scholarly journals Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients

2019 ◽  
Vol 7 (22) ◽  
pp. 3837-3840
Author(s):  
Faridah Baroroh ◽  
Andriana Sari ◽  
Noviana Masruroh
Keyword(s):  
Blood Pressure ◽  
Cost Effectiveness ◽  
Cost Effective ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Significant Difference ◽  
Hypertension Therapy ◽  
The Mean ◽  
The Cost

BACKGROUND: he achievement of optimal hypertension therapy requires cost-effective medicine. The treatment of hypertensive patients needs for long-term medication have made medical costs a prime issue in health economics. AIM: This study aims to determine the cost effectiveness of candesartan therapy compared to candesartan-amlodipine therapy on hypertensive outpatients. METHODS: This is a prospective cohort study that compares candesartan therapy to candesartan-amlodipine therapy at a public hospital from payers’ perspective. The outcome is the percentage of targeted blood pressure decrease after three months of therapy. The cost effectiveness analysis uses the Incremental Cost Effectiveness Ratio (ICER) based on the ratio of cost difference to the outcome in both therapy groups. RESULTS: As many as 111 patients participated in this research, comprising 40 candesartan therapy patients and 71 patients with the combination of candesartan-amlodipine. Of the participants, 63.96% were female, 57.66% were aged 60 or older, and 56.32% had diabetes mellitus as the most common complication. Results show that the average direct medical cost per patient for a therapy of three months with candesartan was IDR 1,050,536 ± 730,007 and IDR 760,040 ± 614,290 for a candesartan-amlodipine therapy. The mean decline of systolic and diastolic blood pressure under candesartan therapy is less than that of candesartan-amlodipine, although without any significant difference (p > 0.05). It follows that the effectiveness of candesartan (85%) is greater than that of the candesartan-amlodipine combination (84.50%). Candesartan therapy is thereby more cost-effective with an ICER value of IDR 580,993/%. CONCLUSION: Hypertension therapy by candesartan is more cost-effective than candesartan-amlodipine therapy with a cost addition of IDR 580,993.

scholarly journals PCV14 COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION THERAPY: ECONOMIC ANALYSIS OF ARBS IN COLOMBIA

2009 ◽  
Vol 12 (7) ◽  
pp. A502
Author(s):  
D Castro ◽  
C Silva ◽  
C Bohorquez-Nassar ◽  
JC Gomez
Keyword(s):  
Cost Effectiveness ◽  
Economic Analysis ◽  
Hypertension Therapy

Cost-effectiveness of dental implants: a utility analysis

1990 ◽  
Vol 54 (11) ◽  
pp. 688-689 ◽  
Author(s):  
J Jacobson ◽  
B Maxson ◽  
K Mays ◽  
J Peebles ◽  
C Kowalski
Keyword(s):  
Cost Effectiveness ◽  
Dental Implants ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document